Skip to main content
OpenTrials
Completed

NCT Number: NCT05933772

Performance Evaluation of Two Silicone Hydrogel Toric Lens Designs in Habitual Soft Contact Lens Wearers

The objective of the study was to compare the clinical performance of two monthly toric silicone hydrogel contact lenses in habitual wearers, when worn for 1-month each.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–39 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Eyes on Sheppard Clinic, Toronto, Ontario, Canada

Loading trial locations.

About this study

This study was a prospective, bilateral eye, subjected-masked, randomized, 1-month cross-over, daily-wear design involving two different silicone hydrogel toric lens types. Each lens type will be worn bilaterally for approximately one month.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Is between 18 and 39 years of age (inclusive) and has full legal capacity to volunteer;
  • Has read and signed an information consent letter;
  • Self-reports having a full eye examination in the previous two years;
  • Anticipates being able to wear the study lenses for at least 8 hours a day, 6 days a week;
  • Is willing and able to follow instructions and maintain the appointment schedule;
  • Habitually wears of toric soft contact lenses binocularly.
  • No more than 1/3 of the participants should be wearing daily disposable soft toric lenses;
  • the remaining 2/3+ of the participants must be planned frequent replacement soft toric lens wearers as follows:
  • i. TOTAL30 for Astigmatism: maximum of 3 (∼10%) (no target percentage)
  • ii. Biofinity toric: maximum of 13 (∼40%) (PLUS a target of minimum 10 (∼30%))
  • iii. Air Optix for Astigmatism (inclusive of +Hydraglyde): maximum of 10 (∼30%) (PLUS a target of minimum 7 (∼20%))
  • iv. ULTRA for Astigmatism: maximum of 5 (∼15%) (no target percentage)
  • v. Acuvue Vita for Astigmatism: maximum of 3 (∼10%) (no target percentage)
  • vi. Acuvue Oasys for Astigmatism: maximum of 10 (∼30%) (no target percentage)
  • vii. Other brands of frequent replacement: maximum of 7 (∼20%) (no target percentage)
  • Has refractive astigmatism of at least -0.75DC but no more than -2.75DC in each eye that is correctable with a soft toric lens with a cylinder power of no greater than -2.25DC;
  • Is ammetropic and requires a spectacle spherical component of +8.00 to -10.00D inclusively;
  • Can be fit and achieve binocular distance vision of at least 20/32 Snellen with the available lens parameters

Exclusion criteria

  • Is participating in any concurrent clinical or research study;
  • Has any known active ocular disease and/or infection that contraindicates contact lens wear;
  • Has a systemic condition that in the opinion of the investigator may affect a study outcome variable;
  • Is using any systemic or topical medications that in the opinion of the investigator may affect contact lens wear or a study outcome variable;
  • Has known sensitivity to the diagnostic sodium fluorescein used in the study;
  • Self-reports as pregnant, lactating or planning a pregnancy at the time of enrolment;
  • Has undergone refractive error surgery or intraocular surgery.

Treatment and study plan

Lens A (comfilcon A toric lens)

Device

One month wear

Lens B (lehfilcon A toric lens)

Device

One month wear

Primary outcomes

  1. Lens Handling on Removal

    Time frame: At the end of one month of wear

    Lens Handling on Removal, using a 0-100 scale (0= very difficult, 100=very easy).

Secondary outcomes

  1. Distance Visual Acuity

    Time frame: At the end of one month of wear

    Distance Visual Acuity, using Snellen converted to logMAR.

Sponsors and collaborators

Lead sponsor

CooperVision International Limited (CVIL)

Industry

Collaborators

  • Centre for Ocular Research & Education, Canada

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Jul 6, 2023
Registry last updated
Mar 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.